NASDAQ · ENLV
Enlivex Therapeutics Ltd.
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
Loading market information…
TLV · BLRX.TA · ILA
Stock price, earnings
Quote as of Oct 29, 2026, 11:38 AM UTC. Cached market data; not a live quote.
One-year closing-price history · ILA. Historical prices are not a forecast.
BioLineRx Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
BioLineRx Ltd.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of -ILA 0.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BioLineRx Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Latest available per-share figures in ILS. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 27, 2025 | ILA 0.01+283.9% vs estimate | ILA 950.25K-82.78% vs estimate |
|---|
| Q4 2024 | Mar 31, 2025 | -ILA 0.01-98.37% vs estimate | ILA 42.81M+52.22% vs estimate |
|---|
| Q3 2024 | Nov 25, 2024 | -ILA 0.02-71.28% vs estimate | ILA 18.45M-5.79% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$2.54-$0.07 (-2.68%)
Enlivex Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.42% below the high.
₪2.50+₪0.05 (+1.87%)
Matricelf Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.68% below the high.
₪3.96-₪0.02 (-0.43%)
Pluri Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.42% below the high.
₪0.23+₪0.01 (+2.71%)
Clal Biotechnology Industries Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.94% below the high.
₪0.01₪0.00 (0.0%)
Purple Biotech Ltd.’s quoted price sits in the upper half of its reported 52-week range, 41.18% below the high.
₪1.85+₪0.04 (+1.93%)
Together Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.8% below the high.
₪2.97-₪0.30 (-9.28%)
BioLight Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.21% below the high.
₪0.01₪0.00 (0.0%)
XTL Biopharmaceuticals Ltd.’s quoted price sits in the lower half of its reported 52-week range, 68.18% below the high.